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THE PROTEINS IN PEMPHIGTJS VTJLGARIS*
IV. DETERMINATION OF THE PLASMA PROTEINS BY ELECTROPHORESIS AND
CHEMICAL FRACTIONATION IN PATIENTS WITH PEMPHIGUS UNDER
TREATMENT WITH ACTH OR CORTISONE
WALTER F. LEVER, M.D., NANCY A. HURLEY, B.S., AND ALICE
E. BLANEY, B.A.
Electrophoretic analysis reveals significant deviations from normal in the
plasma proteins of patients with pemphigus vulgaris (1). In pemphigus vulgaris
acutus, the amount of serum albumin decreases considerably, concomitant with
the advance of the disease, and may decrease to one-third or even one-fourth of
the normal value. On the other hand, the values for a-i and a-2 globulins increase
greatly. In patients in whom the disease has been active for many months the
amount of 'y globulin is also increased. In pemphigus vulgaris chronicus the
electrophoretic changes are similar but much less pronounced. Inasmuch as
ACTH and cortisone have been proved to be of great value in the treatment of
pemphigus, it was thought advisable to study the plasma proteins of patients
with pemphigus before, during and after treatment with these drugs.
Since early 1950, seventeen patients with pemphigus have been treated at the
Massachusetts General Hospital with ACTH or cortisone (2—4). The results have
been very satisfactory. It has been possible to keep the disease under control in
all patients by administering at intervals courses of either ACTH or cortisone in
large doses.
The plasma proteins have been studied in 8 of these patients during a total of
13 courses. Four of the patients had pemphigus vulgaris acutus and showed on
histologic examination intraepidermal bullae with acantholysis; two patients
had pemphigus vulgaris chronicus with subepidermal bullae and no acantholysis;
and 2 patients had pemphigus foliaceus. In addition to electrophoretic analysis,
the plasma proteins were subjected to chemical fractionation in order to obtain
additional information about the lipoproteins and glycoproteins present in the
plasma.
METHODS
Collection of Blood
For each determination 25.5 ml. of blood was drawn into a syringe containing 4.5 ml. of
acid citrate dextrose solution (A.C.D.). The blood cells were removed by centrifugation to
obtain the plasma, designated as "A.C.D. plasma", which was used for electrophoretic
analysis, chemical fractionation and determination of plasma cholesterol and phospholipids.
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The acid citrate dextrose solution used as anticoagulant contained per liter 26.7 g. triso-
dium citrate (5 1120), 8.0 g. citric acid monohydrate, and 22 g. dextrose. At the same time,
approximately 10 ml. of blood was drawn with a dry syringe. Of this about 4 ml. was placed
in a tube containing a small amount of heparin powder for determination of the total pro-
tein; 4 ml. was placed in a tube containing a small amount of potassium oxalate for the
determination of fibrinogen; and 2 ml. was placed in a tube containing the dried residue
of two drops of a solution of 2 per cent potassium oxalate and 3 per cent ammoniuni oxalate
and was used for the determination of the sedimentation rate.
Electrophoresis
Electrophoretic analysis of the A.C.D. plasma was carried out in the Tiselius apparatus
according to the technic described by Longsworth (5). Sodium diethyl barbiturate—sodium
citrate at pH 8.6 and an ionic strength of 0.1 was used as buffer.
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Fm. 1. Distribution of the Various Plasma Proteins in the System of Chemical Frac-
tionation.
Chemical Fractionation
Chemical fractionation was carried out according to the method of Lever and coworkers
(6) which represents an adaptation of Method 10 of plasma fractionation developed by
Cohn and his associates (7). Whereas the latter method is designed for fractionation of large
quantities of plasma, the former represents a tool for analysis of certain of the protein
components in small quantities of human plasma, requiring only 5 ml. of A.C.D. plasma for
the analysis. The fractionation is carried out in a 5° C. bath using low concentrations of
ethanol and various salts, resulting in the concentration of each protein component in an
undenatured state almost exclusively in one fraction or another. In the present system of
analysis the plasma has been separated by filtration into four fractions (Fig. 1).
This method allows determination of albumin, present in Fraction IV+V; of yglobulin,
present as the only major component in Fraction II; of a-i lipoprotein, present in Fraction
IV+V; and of j-1 lipoprotein, present in Fraction 1+111. In addition, the amounts of
glycoprotein can be estimated by the determination of the amount of protein-bound car-
bohydrate (hexose) in each of the four fractions. The amount of hexose in Fraction VI repre-
sents a-i glycoprotein; the amount of hexose in Fraction IV+V corresponds to a-2 glyco-
protein, since neither albumin nor a-i lipoprotein contain any hexose; and the amount of
hexose in Fraction 1+ III represents largely the $ glycoproteins. Fibrinogen determinations
were carried out on plasma rather than on Fraction 1+111.
cx-l Glycoprotein
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Analytic Methods
All analytic determinations, with the exception of the fibrinogen and the sedimentation
rate, were carried out on A.C.D. plasma or its fractions. Since it was realized that the addi-
tion of A.C,D. tothe blood as anticoagulant resulted in an unknown degree of dilution, a
nitrogen determination was carried out on plasma from heparinized blood as well as on
A.C.D. plasma. The factor (N in heparinized plasma / N in A.C.D. plasma) has been applied
to all data obtained on A.C.D. plasma and the various fractions.
Total Nitrogen was determined by the micro-Kjeldahl method. Non-protein nitrogen was
determined after precipitation of the proteins with 20 per cent trichloracetic acid.
Total plasma protein, as used for the conversion of the relative electrophoretic values
into absolute values, was calculated by multiplying the protein nitrogen value obtained on
heparinized blood by 6.73. The factor of 6.73, rather than the more commonly used value of
6.25, was applied in order to include into the calculations not only the peptide moieties but
also the lipid moieties of the lipoproteins. The contribution of the protein-bound lipids to
the eleetrophoretic pattern is nearly equal to that of a corresponding weight of protein (8).
Albumin was determined in Fraction IV+V+VI by the hemin-binding method of Rosen-
feld and Surgenor (9).
y Globulinwas calculated by determination of total protein in Fraction II with the biuret
reaction. For the biuret reaction a modification of the method of Mehl (10) by Lever and
coworkers (6) was used. Since Fraction II contains more than 90 per cent of the yglobulin
in a purity exceeding 90 per cent by electrophoretic measurements, the amount of total
protein in Fraction II was assumed to represent the amount of yglobulin quite accurately.
Lipid analyses were carried out on ethanol extracts of the plasma and of the fractions.
Total cholesterol was determined by the method of Bloor, Pelkan and Allan (11). Lipid
phosphorus was determined by the method of Fiske and SubbaRow (12) following the ashing
procedure of Gortner (13). The factor 25.0 was used to convert lipid phosphorus to phos-
pholipid.
a-I Lipo protein was calculated by multiplying the value for cholesterol in Fraction IV+V
by 6.25. For this calculation the percentage of cholesterol in a-i lipoprotein was taken
as 16 (14).
f3-1 Lipo protein was calculated by multiplying the value for cholesterol in Fraction 1+ III
by 2.86. For this calculation the percentage of cholesterol in 9-1 lipoprotein was taken as
35 (15).
Hexose was determined in the four fractions according to a modification of the method
of Sørensen and Haugaard (16) introduced by Friedman (17). The presence of free carbo-
hydrate (glucose) prevented determination of hexose in whole plasma. Inasmuch as the
percentage of hexose in the various glycoproteins is not yet known the exact quantity of
the various glycoproteins could not be calculated. Nevertheless, changes in the hexose
content of the various fractions can be interpreted as representing changes in the amount
of glycoprotein.
Fibrino yen was determined according to the method of Cullen and Van Slyke (18). The
nitrogen value obtained on the clotted protein with the micro-Kjeldahl method was multi-
plied by the factor 6.0.
Sedimentation rate determinations were carried out according to the method of Wintrobe
and Landsberg (19). The values obtained were corrected to apply to a hematocrit value of
45 per cent.
RESTJLTS
Total Protein and Electrophoretic Analysis of Plasma
The changes in the total plasma protein concentration and in the electrophore-
tic components prior to therapy with ACTII or cortisone were similar to those
reported previously (1). The changes were, however, less pronounced due to the
fact that most patients were placed on treatment before the disease had reached
an advanced stage.
S-
I 0 : 
TA
BL
E 
1 
D
at
a o
bt
ai
ne
d 
by
 el
ec
tro
ph
or
es
is 
an
d f
ra
ct
io
na
tio
n o
f t
he
 p
'as
m
a 
o
f p
at
ie
nt
s 
w
ith
 pe
m
ph
ig
us
 u
n
de
r t
re
at
m
en
t 
w
ith
 A
CT
H
 or
 c
o
rt
iso
ne
 
N
E.
 
PA
TI
EN
T 
D
A
TE
 
E 
o
 
TY
PE
 
A
D
M
IN
. 
M
O
D
E 
O
P 
0 
N
 0 
A
V
ER
- 
A
G
E 
D
O
SE
 
N
 
A
BS
O
L.
 EL
EC
TR
O
EN
O
R.
 
CO
N
CE
N
TR
. 
PR
A
CT
IO
N
A
TI
O
N
 DA
TA
 
SE
D
. 
CO
N
ES
- 
TI
O
N
 
SK
IN
S 
G
EN
- 
c-
 
TS
O
N
5 
N
EM
A
RK
S 
A
 
a-
I 
a-
2 
1 
'Y
 
Fi
b-
 
A
 
ro
t r
in
 
y 
N
or
m
al
 a
v
er
ag
e 
gm
 
ds
ys
 
m
g.
 
gm
/ 
10
0 
gm
./1
00
 m
l. 
x
 
6.
73
 
7.
65
 4.
13
.3
8 
.
69
 1
.0
7j.
61
J .7
7 
gm
./1
00
 m
l. 
4.
lO
j 
.
31
 
j.3
3j.
29
j .
78
 
'/ 0.2 
Pe
m
ph
ig
us
 vu
lg
ar
is 
ac
u
tu
s 
1.
 
St
. 
11
—9
—5
0 
12
—1
—5
0 
12
—
18
—
50
 
1—
2—
51
 
1—
12
—
51
 
3—
12
—
51
 
Cc
irt
. 
A
C
T
H
 
i.
m.
 
i.
m.
 
3.
9 
1.
9 
23
 
12
 
17
0 
6.
36
2.
82
.5
5 
7.
82
3.
58
 .
52
 
15
8 
7.
26
32
8 
.
74
 
7.
05
 3.
44
 .
59
 
7.
42
3.
22
.5
0 
7.
77
3.
30
.5
4 
.
69
 
.
70
 
.
82
 
.
80
 
.
79
 
.
85
 
.
99
.5
7 
1.
51
 .5
3 
1.
22
 .
77
 
1.
16
 .5
9 
1.
30
 .9
2 
1.
36
 .7
1 
.
74
3.
75
 
.
99
4.
12
 
.
42
 2.
93
 
.
47
 3.
44
 
.
69
2.
47
 
1.
03
 
.
42
 
.
68
 
.
36
 
.
34
 
.
54
 
.
28
.5
21
.0
11
 0
.7
 
.
43
 .
28
 1.
03
 
0.
2 
.
34
 .5
7 
.
64
 1
.2
 
.
49
 .5
5 
.
31
 1
.0
 
.
42
.7
1 
.
44
 1
.1
 
0.
5 
p g. f g g e 
p g f g g g 
en
d 
o
f c
o
u
rs
e 
en
d 
o
f 
c
o
u
r
s
e
 
o
ff
 A
C
T
H
 
o
ff
 A
CT
H
 
2.
 
M
o.
 
11
—
27
—
50
 
12
—
13
—
50
 
1—
12
—
51
 
2—
5—
51
 
3—
5—
51
 
A
CT
II 
i.m
. 
6.
7 
27
 
24
9 
5.
84
1.
50
.7
2 
54
52
.2
2 .
53
 
6.
30
 2
.2
5 
.
53
 
7.
76
 3
.1
6 
.
74
 
7.
46
 3
.7
6 
.
31
 1
.0
1 
.
77
 
.
81
 
.
56
 
.
48
 
.
73
.8
61
.0
11
.0
0 
.
65
 .6
9 
.
58
 1.
98
 
.
98
 .8
1 
.
94
 2.
90
 
1.
06
.9
21
.3
33
.0
7 
.
84
 .
79
 1.
08
 
.
17
 
.
21
 
.
26
 
.
44
 
.
29
.5
21
.0
5 
.
09
 .4
4 
.
35
 
.
27
 .5
8 
.
77
 
.
18
 .5
6 
.
87
 1
.6
 
1.
0 
1.
0 
0.
3 
v
.p
. 
p f e e 
v
.p
 
p f g e 
e
n
d 
o
f 
c
o
u
r
s
e
 
o
ff
 A
C
T
H
 
o
ff
 A
C
T
H
 
3.
 
C
a
.
 
1—
23
—5
1 
2—
5—
51
 
2—
26
—
51
 
4—
2—
51
 
4—
16
—5
1 
4—
23
—5
1 
5—
14
—
51
 
5—
23
—
51
 
6—
4—
51
 
C
o
r
t
.
 
A
C
T
I
I
 
o
r
a
l 
fi
.m
. 
'
i.
v.
 
5.
6 
6.
5 
0.
52
 2
4 39
 
13
 
22
5 
16
9 40
 
6.
25
 2
.4
6 .
63
 
7.
60
2.
24
.6
7 
8.
15
 2
.7
4 
.
64
 
7.
69
 3.
38
 .3
9 
7.
51
3.
32
.3
4 
7.
26
3.
18
.5
0 
7.
35
3.
91
.4
4 
7.
45
 3.
57
 .5
3 
6.
64
2.
91
 .5
2 
.
85
 
.
83
 .5
4 
.
91
 3.
64
 
1.
01
 1
.3
4 .
86
1.
46
2.
43
 
1.
14
 1
.2
6 
.
95
1.
34
2.
71
 
.
84
 
1.
12
.6
91
.2
72
.5
4 
.
91
 1
.0
2 
.
69
1.
22
2.
33
 
.
97
 
.
91
.6
61
.0
41
.8
8 
.
95
 
.
86
.5
1 
.
68
2.
64
 
.
97
 
.
92
 .6
7 
.
77
 3.
09
 
.
82
 
.
97
 .6
5 
.
78
2.
69
 .
29
 
.
39
 
.
44
 
.
39
 
.
30
 
.
38
 
.
41
 
.
58
 
.
38
 
.
35
 .3
3 
.
99
 1
.2
 
.
28
.3
31
.6
8 
1.
9 
.
33
 .
40
 1
.7
7 
1.
1 
.
24
 .
27
 1.
59
 0
.9
 
.
21
.3
61
.3
1 
1.
6 
.
14
.3
81
.4
3 
1.
3 
.
13
.2
41
.2
2 
1.
0 
.
15
 .3
0 
.
64
 0
.9
 
.
23
 .4
1 
1.
01
 0
.8
 
p f g f g g g g g 
1 f g I g g g g g 
e
n
d 
o
f 
c
o
u
r
s
e
 
e
n
d 
o
f c
o
u
rs
e 
o
ff 
A
C
T
H
 
4.
 
A
n.
 
5—
0—
51
 
6—
18
—
51
 
A
C
T
H
 
fi
.m
. 
i.
v.
 
3.
3 
17
 
19
2 
6.
73
13
.2
6.
50
 
.
65
 
.
91
.5
9 
.
83
3.
21
 
.
37
 
.
25
.3
41
.0
4 
0.
5 
f 
g
 
0.
09
 
3 
30
 7
.2
83
.8
2.
38
 
.
62
 
.
99
.5
6 
.
91
3.
12
 
.
49
 
.
24
.3
01
.0
2 
0.
4 
g
 
g 
o
ff 
A
CT
II 
Pe
m
ph
ig
us
 vu
lg
ar
is 
ch
ro
ni
cu
s 
5.
 
A
z.
 
10
—
2—
50
 
10
—
16
—
50
 
10
—
30
—
50
 
1—
2—
51
 
1—
23
—
51
 
4—
27
—
51
 
4—
30
—
51
 
5—
7—
51
 
5—
21
—5
1 
6—
11
—5
1 
Co
rt.
 
A
CT
H
 
A
CT
II 
i.m
. 
i.m
. 
i.m
. 
8.
0 
4.
2 
3.
9 
29
 
21
 
22
 
27
6 
20
0 
17
7 
6.
08
 
7.
47
 
7.
25
 
7.
02
 
7.
33
 
6.
38
 
7.
39
 
6.
48
 
6.
52
 
8.
83
 2.
64
 
2.
40
 
3.
50
 
2.
33
 
3.
12
 
2.
09
 
2.
86
 
3.
30
 
3.
51
 
3.
67
 .
47
 
.
75
 
.
44
 
.
91
 
.
46
 
.
38
 
.
45
 
.
32
 
.
55
 
.
71
 
.
69
 
.
89
 
.
65
 
.
72
 
.
64
 
.
66
 
.
79
 
.
57
 
.
62
 
.
89
 
.
88
 
1.
11
 
1.
27
 
.
91
 
1.
17
 
.
87
 
1.
00
 
.
87
 
.
70
 
1.
33
 .
68
 .
71
2.
05
 
.
72
1.
55
}2
.20
 
.
50
 .
96
4.
23
 
.
75
1.
35
2.
64
 
.
63
1.
28
2.
88
 
.
75
1.
65
1.
52
 
.
73
1.
55
2.
54
 
.
34
1.
07
3.
02
 
.
49
 
.
63
 2
.6
7 
.
79
1.
41
4.
19
 
.
41
 
.
25
 
.
59
 
.
12
 
.
48
 
.
16
 
.
28
 
.
54
 
.
67
 
.
33
 
.
40
 
.
39
 
.
51
 
.
30
 
.
35
 
.
19
 
.
23
 
.
23
 
.
34
 
.
32
 .
43
 
.
23
 
.
15
 
.
41
 
.
28
 
.
32
 
.
30
 
.
13
 
.
28
 
.
45
 
.
82
 1
.1
 
.
96
 0
.3
 
1.
02
 
0.
2 
1.
26
 0
.8
 
1.
64
 
0.
5 
1.
55
 1
.0
 
1.
68
 0
.6
 
.
70
 0
.9
 
.
65
 
0.
5 
1.
39
 
1.
0 
p p g p f p f f g f 
f f g f f p f f f I 
en
d 
o
f c
o
u
rs
e 
en
d 
o
f c
o
u
rs
e 
en
d 
o
f 
c
o
u
r
s
e
 
o
ff
 A
C
T
H
 
6.
 
R
o
.
 
1—
2—
51
 
1—
23
—5
1 
C
o
r
t
.
 
o
r
a
l 
2.
5 
21
 
12
0 
7.
91
3.
20
 
6.
83
 3.
04
 .7
3 
.
84
 
.
89
 
.
68
 
.
88
 
.
97
 .
76
 
.
37
 1
.4
5 
3.
47
 
3.
03
 
.
18
 
.
46
 
.
37
 
.
34
 .
52
 
.
19
 1
.0
8 
1.
27
 
1.
3 
0.
1 
p g 
I g 
en
d 
o
f c
o
u
rs
e 
Pe
m
ph
ig
us
 fo
lia
ce
us
 
7.
 
M
e
.
 
10
—3
0-
50
 
12
—1
—5
0 
3—
10
—5
1 
4—
23
—5
1 
6—
11
—
51
 
C
o
r
t
.
 
A
C
T
H
 
i.
m.
 
i.
v.
 
9.
0 
1.
42
 3
3 44
 
27
3 32
 
8.
04
 
7.
95
 
8.
10
 
7.
23
 
8.
75
 3.
62
 
4.
30
 
4.
13
 
4.
10
 
4.
24
 .5
2 
.
59
 
.
62
 
.
35
 
.
82
 
.
93
 
.
74
 
.
72
 
.
59
 
.
79
 1
.3
2 
1.
36
 
1.
13
 
1.
13
 
1.
29
 .8
6 
.
52
 
.
92
 
.
43
 
.
69
 .
78
 
.
44
 
.
58
 
.
62
 
.
88
 2.
70
 
3.
50
 
3.
73
 
3.
26
 
4.
73
 
.
64
 
.
43
 
.
47
 
.
84
 
.
68
 .
56
 
.
63
 
.
51
 
.
33
 
.
42
 .3
6 
.
34
 
.
61
 
.
20
 
.
42
 
.
54
 
.
70
 
1.
14
 
.
85
 
.
94
 1
.2
 
0.
8 
1.
4 
0.
3 
1.
0 
f g f e g 
I g g e e 
e
n
d 
o
f 
c
o
u
r
s
e
 
e
n
d 
o
f c
o
u
rs
e 
o
ff 
A
CT
II 
8.
 
Co
. 
4—
9—
51
 
5—
16
—
51
 
6—
4—
51
 
A
CT
H
 i
.m
. 
3.
2 
37
 
86
 
7.
39
 
7.
25
 
7.
78
 3.
60
 
4.
35
 
3.
91
 .6
4 
.
39
 
.
42
 
.
81
 
.
72
 
.
79
 
.
97
 
.
80
 
1.
07
 .5
5 
.
46
 
.
69
 
.
81
 
.
53
 
.
77
 3.
28
 
4.
15
 
4.
02
 .
55
 
.
78
 
.
64
 
.
21
 
.
18
 
.
29
 .3
2 
.
22
 
.
38
 
.
94
 
.
80
 
.
83
 1
.1
 
0.
1 
0.
9 
f e e 
g g e 
en
d 
o
f c
o
u
rs
e 
o
ff 
A
CT
U
 
A
ve
ra
ge
 va
lu
es
 a
t b
eg
in
ni
ng
 of
 fi
rs
t 
co
u
rs
e 
A
ve
ra
ge
 va
lu
es
 a
t e
n
d 
o
f l
as
t c
o
u
rs
e 
6.
83
2.
89
 
6.
99
i3
.5
1 
.
60
 
.
52
 
.
82
 
.
73
 
.
94
 
.
96
 .6
8 
.
55
 .
91
 
.
73
 2.
89
 
3.
21
 .
38
 
.
34
 
.
55
 .
29
 .4
2 
.
33
 
.
93
 
.
79
 1
.1
 
0.
5 
0 -I 11 
*
 
e
 
=
 e
xc
e
lle
nt
; g
 =
 
go
od
; f
 =
 fa
ir;
 p
 =
 p
oo
r; 
v
.p
. =
 v
e
ry
 po
or
. 
Bo
ld
-ty
pe
d f
ig
ur
es
 in
di
ca
te
 re
su
lts
 ob
ta
i.n
ed
 a
t t
he
 be
gi
nn
in
g o
f t
he
 fir
st 
co
u
rs
e 
an
d 
at
 th
e e
n
d 
o
f 
th
e l
as
t c
o
u
rs
e.
 
th
e c
al
cu
la
tio
n 
o
f t
he
 av
er
ag
e v
al
ue
s. 
Th
ey
 h
av
e b
ee
n 
u
se
d f
or
 
60 TUE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Total Plasma Protein. In 3 of the 4 patients with pemphigus vulgaris acutus
and in 1 of the 2 patients with pemphigus vulgaris chronicus (Patients 1, 2, 3 and
5) the total plasma protein was considerably decreased before treatment, i.e to
values below 6.4 grams per 100 ml. of plasma (Table 1). (This corresponds to a
value of 5.95 grams per 100 ml., if the customary factor of 6.25 had been used
instead of the factor 6.73.) Under treatment the plasma protein rose to normal
values in 3 of the 4 patients.
Electrophoretic Analysis. Before treatment the albumin was below normal in all
instances (Table 1). Very low values, between 1.5 and 2.8 grams per 100 ml., were
obtained in 4 patients. (These are the same patients as those in whom the total
plasma protein was significantly lowered.) The a-i globulin was considerably
elevated in most patients. Amounts greater than 0.6 grams per 100 ml. were
A a 02 Pu 7 A a a P Pa A 01 08 $, Pa 7
FIG. 2. Ascending Electrophoretic Patterns of Patient 2, with Pemphigus Vulgaris
Acutus.
The first pattern was obtained before treatment; the second pattern was obtained after
sixteen days of treatment with ACTII (300 mg. a day i.m. for fourteen days, and 200 mg. a
day i.m. for two days); the third pattern was obtained two months after termination of
treatment. During and following treatment the albumin increased from a very low to a
nearly normal value, while the a-i and a-2 globulin decreased from elevated to normal
values. (For exact data see Table I, patient 2, determinations 1, 2 and 4).
found in 5 patients. (The normal average value is 0.38 grams per 100 ml.). The
a-2 globulin was moderately increased in the majority of patients. The 3-1 globu-
lin showed no significant changes before treatment. The 3-2 globulin (which in
normal plasma consists to approximately equal parts of /3-2 globulin and fibrino-
gen and averages 0.61 grams per 100 ml.) was elevated above 0.75 grams in 3 of the
8 patients. Since the amount of /3-2 globulin is not significantly altered in the
serum of patients with pemphigus (1), it can be assumed that the increase in
/3-2 globulin observed in the plasma of patients with pemphigus was due largely
to an increase in the amount of fibrinogen. The value for ' globulin was normal in
4, slightly elevated in 2, and moderately elevated (above 1 gram per 100 ml.) in
2 patients.
Treatment with ACTH or cortisone produced the following changes: The
albumin rose (Fig. 2) in all but 1 patient; however, a normal value of 4 grams per
100 ml. was attained in only 2 patients. The value for a-i globulin decreased
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during treatment in 5 of the 8 patients, but was still significantly elevated at the
end of treatment in several patients. Similarly, the a-2 globulin showed a tend-
ency to decrease. The $-1 globulin did not change significantly under treatment.
The 9-2 globulin components, which contains the fibrinogen, decreased in all
patients in whom it had been elevated except in 1 (Patient 3). In 3 patients (Pa-
tients 6, 7 and 8) it fell to subnormal levels, namely 0.37, 0.43 and 0.46 grams
per 100 ml. of plasma, as compared with a normal average value of 0.61 grams.
They globulin decreased under treatment in all but 1 patient (Patient 4 who had
received treatment for only 20 days). At the end of treatment the 'y globulin was
still slightly elevated in 3, normal in 3, and below normal in 2. In the latter
2 patients (Patients 1 and 8) the y globulin decreased from normal values of 0.74
and 0.81 grams per 100 ml. to 0.47 and 0.53 grams per 100 ml., respectively.
Chemical Fractionation of Plasma
Albumin, 'y Globulin. The values for albumin and yglobulin obtained by chem-
ical fractionation corresponded, on the whole, quite closely to the values obtained
by electrophoretic analysis (Table 1).
Hexose. The amount of protein-bound sugar, or hexose, indicates the amount
of glycoprotein present. Prior to therapy the total amount of hexose in the plasma
(calculated on the amount present in all four fractions) was greatly increased in
all patients (Table 2). Study of the amount of hexose in the various fractions re-
vealed that the increase was confined entirely to Fractions IV + V and VI, which
contain the a-2 glycoprotein and the a-i glycoprotein, respectively. The average
hexose content in Fraction IV + V before treatment was 97 mg. per 100 ml.
(which is more than twice the normal average amount of 45 mg. per 100 ml.);
while in Fraction VI the average amount was 33 mg. per 100 ml. (which is twice
the normal average amount of 15 mg. per 100 ml.). The values for hexose in
Fraction I + III, representing largely the 3 glycoproteins, were within normal
limits.
Under treatment the amount of a-i glycoprotein decreased in 5 patients, and
the amount of a-2 glycoprotein decreased in 4 patients. Nevertheless, the values
for the two a glycoproteins remained significantly elevated in most patients. The
amount of glycoproteins remained within normal limits.
Fibrinogen. The values for fibrinogen (Table 1) were elevated prior to treatment
in all patients. The increase was considerable in 3 patients, amounting to values
above 0.5 grams per 100 ml., as compared with a normal average value of 0.29
grams.
Under treatment the fibrinogen decreased in 6 patients, while in 2 it remained
elevated above a value of 0.5 grams per 100 ml. In 3 patients the amount of
fibrinogen decreased to subnormal values, namely 0.19, 0.20 and 0.22 grams per
100 ml., respectively. (These are the same patients as those in whom the electro-
phoretic 3-2 component decreased below normal under treatment.)
Lipo proteins. Almost all, if not all, of the cholesterol and phospholipids present
in the plasma is bound to proteins as lipoproteins. The amounts of cholesterol and
phospholipids in the various fractions therefore indicate the amount of lipopro-
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tein present in them. There are two major lipoproteins, namely a-i lipoprotein,
present in Fraction IV + V, and fl-i lipoprotein, present in Fraction I + III.
Small amounts of lipoprotein usually are found in Fraction II which is largely
composed of globulin. It is likely that the lipoprotein in Fraction II is a con-
taminant rather than a distinct lipoprotein. The value for a-i lipoprotein and
fl-i lipoprotein can be calculated from the amounts of cholesterol present in
Fraction IV + V and I + III, respectively, since the cholesterol content of these
two lipoproteins is known.* (For calculations see Analytical Methods.)
The total cholesterol values in the plasma before treatment were within normal
limits in 6 of the 8 patients (Table 2). A low value, 121 mg. per 100 ml., was found
in a patient who was very ill with advanced pemphigus vulgaris acutus (Patient
2). One patient with pemphigus foliaceus and essential hypertension (Patient 7)
had hypercholesteremia of 315 mg. per 100 ml. This high value probably was not
related to the pemphigus foliaceus. The amounts of cholesterol in Fractions I +
III (fl-i lipoprotein) and IV + V (a-i lipoprotein) were within normal limits in
all patients except the 2 patients with hypocholesteremia and hypercholesteremia,
respectively.
Under treatment the plasma cholesterol increased in 5 patients, showed no
essential change in 1, and decreased in 2. The average level rose from 198 to 22i
mg. per 100 ml. Temporary hypercholesteremia was induced in 2 patients: in 1
patient the total cholesterol rose during one course from 194 to 303 mg. per 100
ml., and in the other from 178 to 318 mg. per 100 ml. (Patients 1 and 5). Of the
two lipoprotein-containing fractions, Fraction I + III, representing fl-i lipopro-
tein, showed no significant change in cholesterol under treatment. In Fraction
IV + V, however, representing a-i lipoprotein, a considerable increase in choles-
terol occurred during treatment, from an average of 61 to 88 mg. per 100 ml. An
increase occurred in all patients but 1 (Patient i). In this patient, however, a
determination ten days after cessation of therapy revealed a substantial rise of
the cholesterol level in Fraction IV + V from 55 mg. per 100 ml. at the end of
treatment to 86 mg.
In order to ascertain how long the increase in cholesterol in Fraction IV + V
persisted, determinations were carried out at varying intervals after cessation of
therapy. As shown in Table 3, a substantial increase in the amount of choles-
terol in Fraction IV + V following cessation of therapy was noted in 2 patients
after ten and forty-three days, respectively, whereas a fall of the cholesterol value
was noted in 7 determinations and no essential change in 2. A comparison of the
values obtained some time after the last treatment with those obtained before
treatment showed that there was no tendency of ACTII or cortisone to induce a
persistent increase of the cholesterol in Fraction IV + V.
The values for total plasma phospholipids paralleled those for cholesterol
closely. Before treatment the values were normal in all patients except the
patient with essential hypertension (Patient 7) who had an elevated value. The
* The assumption is made that the percentage of cholesterol in a-i and -i lipoprotein
remains constant even when the amount of cholesterol is increased. That this is a fact re-
mains to be proven.
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amount of phospholipids in Fraction I + III (-1 lipoprotein) and IV + V (a-i
lipoprotein) were also normal in all patients but Patient 7.
Under treatment the total plasma phospholipids increased in amount in 4
patients, showed no essential change in 2, and decreased in 2. The average level
rose from 222 to 234 mg. per 100 ml. Of the two lipoprotein fractions, Fraction
I + III, the 3-1 lipoprotein fraction, showed no significant change in the amount
of phospholipids under treatment. In Fraction IV + V, however, the a-i lipo-
protein fraction, a significant increase in the phospholipids occurred in 4 patients,
TABLE 3
Value of cholesterol in Fraction IV + V (a-i lipo protein) before treatment with ACTH or
cortisone, at end of treatment, and following an interval without treatment
NUMBER
OF
PATIENT
VALUE
BEFORE
TREATMENT
VALUE FOLLOWINGVALUE AN INTERVALAT END OF WITHOUTTREATMENT TREATMENT
LENGTH
OF INTERVAL
WITHOUT
TREATMENT
DIFFERENCE
BETWEEN
VALUE AT END
OF TREATMENT
AND VALUE
FOLLOWING
AN INTERVAL
WITHOUT
TREATMENT
DIFFERENCE
BETWEEN
VALUE BEFORE
TREATMENT
AND VALUE
FOLLOWING
AN INTERVAL
WITHOUT
TREATMENT
1
mg./100 ml.
68
mg./lOO ml.
109 —÷ 57
55— 86
days
17
10
mg./100 ml.
—52
+31
mg./100 ml.
—11
+20
2 24 41—÷ 70 43 +29 +43
3 47 70—* 62
92 —÷ 60
35
12
—8
—32
+15
+13
5 65 94 —÷ 19
77 —' 25
107 — 53
64
94
21
—75
—52
—54
—46
—40
—12
7 103 69 —+ 75
134—108
57
49
+ 6
—26
—28
+5
8 88 124 —* 102 19 —22 +14
and no essential change in 4. The average value rose from 117 to 138 mg. per
100 ml.
Calculation of the values for a-i and 3-i lipoproteins on the basis of their
cholesterol content revealed under treatment a considerable increase in the
average value for a-i lipoprotein from 0.38 to 0.55 grams per 100 ml. of plasma.
No significant change occurred in the average value for 3-1 lipoprotein.
Sedimentation Rate
The sedimentation rate before treatment was elevated in all patients and, cor-
rected to a hematocrit value of 45 per cent, averaged 1.1 mm. per minute, as com-
pared with a normal value of 0.2 mm. The sedimentation rate decreased under
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treatment in all patients. The average sedimentation rate after treatment was
0.55 mm. per minute (Table 1).
DISCUSSION
The most important electrophoretic findings before treatment were a marked
decrease in albumin, and an increase in a-i globulin, a-2 globulin, fl-2 globulin
and y globulin (Figure 3). Chemical fractionation studies revealed a considerable
increase in the a-i and a-2 glycoproteins, suggesting that the increase in the
electrophoretic a-i and a-2 globulin components was due to an increase in
glycoprotein. The values for the a-i and fl-i lipoproteins were normal. Corre-
BEFORE TREATMENT
ELECTROPHOR. FRACTIONAl.
AFTER TREATMENT
ELECTROPHOR. FRACTIONAl.
ALBUMIN — — —— — —
O—I GLOBULIN
O—I GLYCOPROTEIN
—I LIPOPROTEIN
-I- +
1- ÷
ii
+
+
+ +
(X—2 GLOBULIN
G—2 GLYCOPROTEIN
+
-p 1-
(1-)
1-
,3—i GLOBULIN
/3 GLYCOPROTEINS
/3—I LIPOPROTEIN
n
I'
n
fl
fl
,—2 GLOBULIN
FIBRINOGEN
+ +
+ +
fl
n
y GLOBULIN + + n fl
Fin. 3. Tabulation of the Changes Observed by Electrophoresis and Chemical Fractiona-
tion in the Various Plasma Protein Components Before and After Treatment.
(n = normal; (+) = slightly increased; + = moderately increased; ++ = greatly in-
creased; — = moderately decreased; —— = greatly decreased.)
sponding to the increase in the electrophoretic fl-2 globulin component there was
a significant increase in fibrinogen on chemical analysis.
Under treatment with ACTH or cortisone all abnormal values showed a shift
in the direction of normal; but the values did not reach normal in all patients
while treatment was administered. Especially the values for the a-i and a-2
globulins on electrophoretic analysis and for the a-i and a-2 glycoproteins on
chemical analysis tended to remain elevated. It should be noted, however, that
in Patient 2 in whom the disease remained fully under control for several months
after the last treatment a further shift of the electrophoretic values for a-i and
a-2 globulin toward normal occurred (Figure 2). Even then, however, the value
for a-2 glycoprotein was still elevated indicating that this glycoprotein is very
slow in returning to a normal value.
It is likely that in most plasma protein components the shift toward normal
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under treatment with AUTH or cortisone is not a direct effect of these drugs,
but is brought about indirectly through improvement of the disease by the
drugs. There were three proteins, however, on which AUTH and cortisone ap-
peared to exert a direct effect, namely 'y globulin, fibrinogen and a-i lipoprotein.
Globulin. The y globulin, which decreased under treatment in all but 1 pa-
tient in spite of the tendency of the disease to induce a rise of the y globulin, fell
in 4 of the 8 patients either during or at the end of one of the courses to values
below normal (Patients 1, 2, 7 and 8). The lowest values obtained by electro-
phoretic analysis in these 4 patients were: 0.42, 0.58, 0.44 and 0.53 grams per 100
ml., respectively. It is thus very likely that AUTH and cortisone actively sup-
press the formation of y globulin. Previous investigators have studied the effect
of ACTH and cortisone on 'y globulin. Vaughan, Bayles and Favour (20) noted
a decrease in the elevated globulin levels in 10 patients with rheumatoid arthritis,
in 4 with scieroderma and in 5 with systemic lupus erythematosus. Soffer, Levitt
and Baehr (21) found in 5 patients with systemic lupus erythematosus a decrease
in globulin from an average of 29.6 per cent to 19.5 per cent. Lever, Schultz and
Hurley (22) noted in 5 patients with scleroderma and 1 patient with systemic
lupus erythematosus a considerable lowering of the globulin under treatment in
every case. In 2 of the patients with scieroderma who had had initially normal
amounts of globulin the globulin fell to subnormal levels. On the other hand,
Bernfeld, Bonner and Homburger (23) found a decrease in globulin in only 1 of
45 patients with various diseases.
Fibrinogen. The 3-2 globulin of the electrophoretic pattern (which contains the
fibrinogen) and the fibrinogen itself when determined chemically showed under
treatment with ACTH or cortisone a significant decrease in most patients. A
decrease to subnormal values was observed in 4 of the 8 patients either during or
at the end of one of the courses (Patients 5, 6, 7 and 8). The lowest values for
fibrinogen obtained in these 4 patients were: 0.13, 0.19, 0.20 and 0.22 grams per
100 ml. As in the case of globulin, this finding suggests an active inhibition of
fibrinogen formation by AUTH and cortisone.
a-i Lipoprotein. Au increase in the a-i lipoprotein from normal to abnormally
high values was observed in all patients receiving AUTH or cortisone. Both the
cholesterol and the phospholipid content of the a-i lipoprotein increasod. In con-
trast, the j3-1 lipoprotein remained essentially unchanged. The increase in the
a-i lipoprotein continued in 2 patients for some time after discontinuance of
therapy, but in all other patients the value for a-i lipoprotein decreased after
cessation of therapy, usually to pretreatment levels.
That AUTH and cortisone have an effect on the lipid metabolism has been
noted by several observers. Uonn, Vogel, Louis and Fajans (24) who administered
short courses of AUTH lasting from six to nine days to 3 normal men observed a
significant decrease in total cholesterol, especially in the esterified fraction, be-
tween the third and fifth days. On the other hand, Adlersberg, Schaeffer and
Drachman (25) who administered AUTH or cortisone over long periods of time
found, as we have observed, an elevation of both the cholesterol and the phos-
pholipids in 36 out of 47 courses. This increase occurred more often in patients
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receiving long courses extending over sixty days than in patients treated with
short courses. Hypercholesteremia with values above 280 mg. per 100 ml. of
plasma developed during 7 of the 8 long courses. The increase in cholesterol con-
cerned both the free and esterified fraction so that the ratio between the two
fractions remained undisturbed. Sprague and coworkers (26) found an increase
in the total plasma cholesterol during the administration of cortisone in 4 out of
6 patients. The conclusion that can be drawn from these observations is that
immediately after or within the first few days of treatment with ACTH or corti-
sone the cholesterol may fall, but that prolonged administration is liable to induce
a rise in serum cholesterol and phospholipids.
The reason for the increase in a-i lipoprotein observed by us in all patients
under treatment with ACTH or cortisone is obscure. Preliminary studies carried
out in this laboratory on patients with disturbances of the lipid metabolism have
revealed that in nephrosis, biliary cirrhosis, myxedema, primary familial xantho-
matosis and essential hyperlipemia the increase in lipoprotein is confined to the
3-i lipoprotein and that in some of the patients with these diseases, especially
those with nephrosis, the a-i lipoprotein is actually decreased in amount.
Sedimentation Rates. Correlation of the sedimentation rates with the electro-
phoretic and fractionation data revealed no absolute relationship with any one
component. Nevertheless, the best correlation existed with the $-2 globulin com-
ponent of the electrophoretic pattern (which contains the fibrinogen) and with
the fibrinogen as determined by chemical analysis. As a rule, the sedimentation
rate decreased as the amount of fibrinogen decreased. However, in several pa-
tients the sedimentation rate was found to be elevated although the fibrinogen re-
vealed normal values. In such patients the a-globulin values were still elevated
(Patient 3, determinations 2 and 4; Patient 8, determination 1). Thus, high values
for the a globulins seemed to accelerate the sedimentation rate. In addition, a low
value for albumin tended to be associated with a high sedimentation rate. No
correlation, however, was noted with y globulin. In several patients the sedimen-
tation rate was low while globulin was elevated (Patient 1, determination 2;
Patient 5, determination 2; Patient 6, determination 2).
SUMMARY
Electrophoretic and chemical fractionation studies of the plasma proteins were
carried out on patients with pemphigus before and after treatment with ACTH
or cortisone.
Before treatment, electrophoretic studies revealed: a decrease in albumin and
an increase in the a-i, a-2, 3-2 and y globulin. Chemical fractionation studies
revealed that the increase in the electrophoretic a-i and a-2 globulin components
was due to a considerable increase in the a-i and a-2 glycoproteins; and that the
increase in the electrophoretic 3-2 component was due to an increase in fibrinogen.
Determination of the a-i and -i lipoproteins by chemical fractionation revealed,
as a rule, normal values.
Under treatment there was an increase in albumin. The values of the a-i and
a-2 globulins obtained by electrophoretic analysis and the values of the a-i and
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a-2 glycoproteins obtained by chemical fractionation decreased but still re-
mained elevated in many instances. The fibrinogen and the y globulin decreased
in almost all instances. They decreased in several instances to subnormal values,
suggesting that ACTH and cortisone actively suppress the formation of fibrinogen
and ' globulin.
The a-i lipoprotein increased from normal to abnormally high values in all
patients while treatment with ACTH or cortisone was administered. The fl-i
lipoprotein, on the other hand, remained normal. The elevated values for a-i
lipoprotein decreased to normal in most patients within a few weeks after treat-
ment with ACTH or cortisone was discontinued.
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DISCUSSION
DR. BLANK, Philadelphia: I wondered if these changes which you described
with ACTH or cortisone are also seen in patients, with other diseases, who re-
ceived these drugs, or are some of these changes with the drugs specific for
patients with pemphigus.
DR. LEVER: In answer to Dr. Blank's question: The changes which I have
described are not specific for pemphigus. Other severe cutaneous diseases, such
as generalized exfoliative dermatitis, reveal the same pattern, namely: a marked
decrease in albumin and an increase in the alpha glycoproteins, in fibrinogen and
in gamma globulin. These deviations decrease on treatment with ACTH or
cortisone.
The increase in alpha lipoprotein which I described is not in any way due to
pemphigus. It is brought about by the treatment with ACTH or cortisone and
occurs also in other diseases when treated with these drugs.
